A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
作者： V Valero , S E Jones , D D Von Hoff , D J Booser , R G Mennel
DOI: 10.1200/JCO.1998.16.10.3362
关键词:
摘要: PURPOSETo evaluate the efficacy and safety of docetaxel in patients with paclitaxel-resistant metastatic breast cancer (MBC).PATIENTS AND METHODSDocetaxel (100 mg/m2) was administered every 3 weeks to 46 registered at four centers. Patients had previously received < or = two chemotherapy regimens for MBC. All progressive disease while receiving paclitaxel therapy. Treatment repeated until there evidence progression a maximum three cycles after best response.RESULTSObjective responses were seen eight 44 assessable (18.1%; 95% confidence interval [CI], 6.7% 29.5%). Seven partial one patient responded completely. Response rates not significantly different by dose resistance. No 12 who 24-hour infusion, but response rate 32 1- 3-hour infusion 25%. The med...
sci-hub.se 参考文章(23)
Fennelly D, Seidman Ad, Norton L, Baselga J, Hudis Ca, Raptis G, Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience. Oncology. ,vol. 11, pp. 20- 28 ,(1997)
J M Andreu, J F Díaz, R Gil, J M de Pereda, M García de Lacoba, V Peyrot, C Briand, E Towns-Andrews, J Bordas, Solution structure of Taxotere-induced microtubules to 3-nm resolution. The change in protofilament number is linked to the binding of the taxol side chain. Journal of Biological Chemistry. ,vol. 269, pp. 31785- 31792 ,(1994) , 10.1016/S0021-9258(18)31764-2
J.H. Beijnen, I.A.M. Mandjes, W.W. ten Bokkel Huinink, M.T. Huizing, J.B. Vermorken, H.M. Pinedo, F. Bierhorst, J.J. Heimans, B. Winograd, T.J. Postma, High dose Paclitaxel with Granulocyte Colony-stimulating factor in patients with advanced breast cancer Refractory to Anthracycline Therapy: A European Cancer Centre Trial Seminars in Oncology. ,vol. 22, pp. 16- 22 ,(1995)
R B Livingston, G K Ellis, J R Gralow, M A Williams, R White, C McGuirt, B B Adamkiewicz, C A Long, Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. Journal of Clinical Oncology. ,vol. 15, pp. 1395- 1400 ,(1997) , 10.1200/JCO.1997.15.4.1395
P Eisenberg, M Kane, W A Bierman, J Mortimer, E Genevois, R E Bellet, P M Ravdin, H A Burris, G Cook, Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. Journal of Clinical Oncology. ,vol. 13, pp. 2879- 2885 ,(1995) , 10.1200/JCO.1995.13.12.2879
A D Seidman, D Hochhauser, M Gollub, B Edelman, T J Yao, C A Hudis, P Francis, D Fennelly, T A Gilewski, M E Moynahan, V Currie, J Baselga, W Tong, M O'Donaghue, R Salvaggio, L Auguste, D Spriggs, L Norton, Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. Journal of Clinical Oncology. ,vol. 14, pp. 1877- 1884 ,(1996) , 10.1200/JCO.1996.14.6.1877
Françoise Guéritte-Voegelein, François Lavelle, Daniel Guénard, Marie-Christine Bissery, Experimental Antitumor Activity of Taxotere (RP 56976, NSC 628503), a Taxol Analogue Cancer Research. ,vol. 51, pp. 4845- 4852 ,(1991)
Carlo M. Croce, Aruna Basu, Subrata Haldar, Bcl2 Is the Guardian of Microtubule Integrity Cancer Research. ,vol. 57, pp. 229- 233 ,(1997)
V Valero, F A Holmes, R S Walters, R L Theriault, L Esparza, G Fraschini, G A Fonseca, R E Bellet, A U Buzdar, G N Hortobagyi, Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. Journal of Clinical Oncology. ,vol. 13, pp. 2886- 2894 ,(1995) , 10.1200/JCO.1995.13.12.2886
Marie-Christine Bissery, Gerhard Nohynek, Ger-Jan Sanderink, François Lavelie, Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part I: preclinical experience Anti-Cancer Drugs. ,vol. 6, pp. 339- 355 ,(1995) , 10.1097/00001813-199506000-00001